Company Interview / Pro Medicus punished despite record result

Key Points:

Pro Medicus (ASX:PME) reports a 230% rise in net profit, $278 million in new contractsExcluding investment gains, profit rises 30%Shares experience largest one-day fall in 14 years, dropping 21%AI integration viewed as an opportunity for efficiency and accuracy, not a margin threat

Pro Medicus (ASX:PME) has reported a significant jump in first half net profit, surging nearly 230% to $171 million, while revenue grew 28% to $125 million. Shareholders are set to receive an interim dividend of $0.32 per share. CEO Dr Sam Hupert highlights that if an unrealised $149 million gain from a $10 million investment in 4D Medical is excluded, net profit after tax rises around 30%. Despite record North American revenue growth exceeding 30% and six new contracts in the region worth $278 million, shares dropped approximately 21%, the largest single-day fall in 14 years. Hupert attributes this to market expectations being skewed by the impact of the investment gain.

Hupert clarifies that Pro Medicus does not provide specific financial guidance, adhering to its longstanding approach. He points to the business's strong contract pipeline, expressing confidence in growth, particularly with new offerings in cardiology and prestigious wins such as the University of Heidelberg contract in Europe.

On the topic of artificial intelligence, Hupert rejects suggestions that AI will compress margins, maintaining that proprietary software and long-term contracts insulate the company. He sees AI as an efficiency enabler rather than a threat, positioning Pro Medicus to benefit from its integration into healthcare imaging solutions.